Hyperemesis gravidarum: Difference between revisions

No edit summary
Line 55: Line 55:
==Disposition==
==Disposition==
*Discharge if able to tolerate PO and ketonuria resolved
*Discharge if able to tolerate PO and ketonuria resolved
*Admit if:
 
**Uncertain diagnosis
===Admit===
**Intractable [[vomiting]]
*Uncertain diagnosis
**Persistent ketonemia or [[electrolyte abnormalities]] after [[volume repletion]]
*Intractable [[vomiting]]
**Weight loss >10% of prepregnancy weight
*Persistent ketonemia or [[electrolyte abnormalities]] after [[volume repletion]]
*Weight loss >10% of pre-pregnancy weight


==References==
==References==

Revision as of 13:45, 18 January 2017

Background

  • Simple nausea and vomiting affects 60-80% of patients during first 12wk of pregnancy
  • Hyperemesis gravidarum only affects 0.3-2% of pregnancies[1]
  • Hyperemesis gravidarum defined as intractable vomiting with at least 1 of following:

Clinical Features

  • Persistent nausea and vomiting
  • Signs of volume depletion
  • Note: Abdominal pain is highly unusual and should prompt consideration of a different diagnosis

Differential Diagnosis

Nausea and vomiting in pregnancy

Evaluation

Management

Antiemetics

ACOG recommends a stepwise approach to nausea and vomiting in pregnancy[2]

Medication Pregnancy Drug Class
Vitamin B6 A
Dimenhydrinate B
Doxylamine B
Ondansetron B
Metoclopramide C
Promethazine C

Rehydration

  • PO fluids if able to tolerate
  • IV fluids (use fluid containing D5 in the setting of ketonuria)

Disposition

  • Discharge if able to tolerate PO and ketonuria resolved

Admit

References

  1. Goodwin, TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am. 2008 Sep;35(3):401-17
  2. Nausea and vomiting of pregnancy. ACOG Practice Bulletin No. 153. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2015; 126(3):e12-24
  3. Fejzo MS, et al. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016 Jul;62:87-91.